Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Research & Development (2016 - 2025)

Ani Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $12.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 26.34% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $51.7 million, up 15.89%, while the annual FY2025 figure was $51.7 million, 15.89% up from the prior year.
  • Research & Development for Q4 2025 was $12.3 million at Ani Pharmaceuticals, roughly flat from $12.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $16.6 million in Q4 2024 and bottomed at $2.5 million in Q3 2021.
  • The 5-year median for Research & Development is $7.5 million (2022), against an average of $8.2 million.
  • The largest annual shift saw Research & Development crashed 53.22% in 2021 before it skyrocketed 211.77% in 2022.
  • A 5-year view of Research & Development shows it stood at $3.1 million in 2021, then skyrocketed by 66.31% to $5.2 million in 2022, then soared by 88.95% to $9.9 million in 2023, then surged by 68.7% to $16.6 million in 2024, then decreased by 26.34% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Research & Development are $12.3 million (Q4 2025), $12.3 million (Q3 2025), and $16.5 million (Q2 2025).